MET and cancer: TAS-115, as a multi-targeted kinase inhibitor, disrupts pro-survival signaling by blocking c-MET/HGF and VEGFR2 pathways, thereby attenuating downstream PI3K/Akt/mTOR activation and diminishing the ability of cancer cells to withstand stress [29].